The addition of #brentuximab_vedotin shows survival benefits in patients with previously untreated stage III or IV classic #Hodgkin’s_lymphoma. The ECHELON-1 phase 3 trial tested the addition of the CD30-directed #Antibody_drug_conjugate brentuximab vedotin to doxorubicin, vinblastine, and dacarbazine (A+AVD), versus the standard doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in the first line setting. The 6-year overall survival estimates were 93.9% in the A+AVD group and 89.4% in the ABVD group.
.png)